This article is a correction to:
Impact of a DSS-supported medication review on the safety of drug therapy and quality of life in patients with antithrombotic therapy
Tanja Elnaz Hassanzadeh
Carina Hohmann
Carsten Culmsee- 1Pharma4u GmbH, Munich, Germany
- 2Institute for Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, University of Marburg, Marburg, Germany
- 3Department of Pharmacy, Klinikum Fulda gAG, Fulda, Germany
A Corrigendum on
Impact of a DSS-supported medication review on the safety of drug therapy and quality of life in patients with antithrombotic therapy
by Hassanzadeh TE, Hohmann C and Culmsee C (2024). Front. Pharmacol. 15:1194201. doi: 10.3389/fphar.2024.1194201
In the published article, there was an error. The M and SD for the index value were incorrect.
A correction has been made to 3 Results, 3.3 Quality of life. This sentence previously stated:
“First, the descriptive part shows a statistically significant improvement of the index value from M = 0.90 (SD = 0.9) to M = 1.1 (SD = 1.2), second, the evaluation of the VAS improved from M = 67.3 (SD = 14.4) to 73.0 (SD = 13.4).”
The corrected sentence appears below:
“First, the descriptive part shows a statistically significant improvement of the index value from M = 0.81 (SD = 0.2) to M = 0.88 (SD = 0.1), second, the evaluation of the VAS improved from M = 67.3 (SD = 14.4) to 73.0 (SD = 13.4).”
In the published article, there was an error. The M value for QoL, EQ Index was incorrect.
A correction has been made to 4 Discussion, Paragraph 3. This sentence previously stated:
“The difference between the pre- and post-intervention groups was relatively small, with M = 2.4 (adherence), M = 5.7 (QoL, EQ VAS) and M = 0.2 (QoL, EQ Index), respectively.”
The corrected sentence appears below:
“The difference between the pre- and post-intervention groups was relatively small, with M = 2.4 (adherence), M = 5.7 (QoL, EQ VAS) and M = 0.07 (QoL, EQ Index), respectively.”
The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: drug safety, medication review, community pharmacy, interprofessional collaboration, polypharmacy, quality of life, antithrombotic medication
Citation: Hassanzadeh TE, Hohmann C and Culmsee C (2024) Corrigendum: Impact of a DSS-supported medication review on the safety of drug therapy and quality of life in patients with antithrombotic therapy. Front. Pharmacol. 15:1507320. doi: 10.3389/fphar.2024.1507320
Received: 07 October 2024; Accepted: 22 October 2024;
Published: 31 October 2024.
Edited and reviewed by:
Bernd Rosenkranz, Fundisa African Academy of Medicines Development, South AfricaCopyright © 2024 Hassanzadeh, Hohmann and Culmsee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tanja Elnaz Hassanzadeh, hassanzadeh@wir-machen-amts.de; Carsten Culmsee, culmsee@staff.uni-marburg.de